ArkBio Publishes Pivotal Phase 3 Data for Azstarys in Chinese Children with ADHD – NMPA‑Approved Dual‑Release Formulation Nears Commercial Launch
CompanyDrug

ArkBio Publishes Pivotal Phase 3 Data for Azstarys in Chinese Children with ADHD – NMPA‑Approved Dual‑Release Formulation Nears Commercial Launch

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced that results from the pivotal Phase 3 trial of Azstarys™ (serdexmethylphenidate chloride and dexmethylphenidate hydrochloride capsules) in Chinese children aged 6–12 years with…

GenFleet's Oral KRAS G12D Inhibitor GFH375/VS‑7375 Delivers Positive Data Across Global Studies – World's First KRAS G12D Agent in Phase III for NSCLC and Pancreatic Cancer
CompanyDrug

GenFleet’s Oral KRAS G12D Inhibitor GFH375/VS‑7375 Delivers Positive Data Across Global Studies – World’s First KRAS G12D Agent in Phase III for NSCLC and Pancreatic Cancer

Centergate Technologies Subsidiary Duoduo Pharmaceutical Has Calcium Dobesilate Capsules Application Accepted by NMPA – Generic Filing Enters Review for Established Capillary Protectant
CompanyDrug

Centergate Technologies Subsidiary Duoduo Pharmaceutical Has Calcium Dobesilate Capsules Application Accepted by NMPA – Generic Filing Enters Review for Established Capillary Protectant

Tasly Pharmaceutical Receives NMPA Clinical Trial Approval for TDX105 Granules – Category 1.1 TCM Innovative Drug Targeting Chemotherapy‑Induced Hand‑Foot Skin Reactions
CompanyDrug

Tasly Pharmaceutical Receives NMPA Clinical Trial Approval for TDX105 Granules – Category 1.1 TCM Innovative Drug Targeting Chemotherapy‑Induced Hand‑Foot Skin Reactions

Sino Biopharmaceutical's Hepatitis B Assets Take Center Stage at AASLD 2026 – Bepirovirsen Phase 3 Functional Cure Data and TQ‑A3334 Late‑Breaking Phase II Results Slated for Oral Presentation
CompanyDrug

Sino Biopharmaceutical’s Hepatitis B Assets Take Center Stage at AASLD 2026 – Bepirovirsen Phase 3 Functional Cure Data and TQ‑A3334 Late‑Breaking Phase II Results Slated for Oral Presentation

- Advertisement -
Ad image
Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline
CompanyDeals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

CompanyMedical Device

Jenscare’s LuX-Valve Plus Secures CE Mark as World’s Second Transcatheter Tricuspid Valve Replacement

Others

Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3/4 Inhibitor TQC3721

CompanyDrug

Mabwell Bioscience Secures NMPA Approval for 9MW5211 Antibody in Type 1 Diabetes, Expanding Autoimmune Pipeline

CompanyDrug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy
Others

AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy

Others

OTR Therapeutics Partners with LG Chem to Accelerate Early-Stage Oncology Programs with China-Global Development Model

Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus
CompanyDrug

Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus

Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis
CompanyDrug

Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis

CompanyDeals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

CompanyDeals

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Show More